LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows
PR Newswire•29/10/2026•09:00 ET
0
Key Highlights
- ➤Esketamine cut depression severity meaningfully for 74% of 258 patients after 12 weeks
- ➤TMS cut depression severity meaningfully for 61% of 355 patients after 30 sessions
- ➤Specialty-service locations more than doubled to 69 from 33 versus Q3 2025
- ➤Esketamine availability expanded to 18 states; TMS reached 22 states
- ➤LifeStance plans substantial specialty-services footprint expansion in 2027
Expert Statements
Dr. Stephanie Eken, Chief Medical Officer, LifeStance Health
“For patients with treatment-resistant depression, not finding relief from previous treatments does not mean they are out of options.”
Dr. Stephanie Eken, Chief Medical Officer, LifeStance Health
“The improvements we’re seeing at LifeStance with esketamine and TMS offer new hope for patients who have continued to struggle, including those experiencing the most severe symptoms and suicidal ideation.”
Dr. Stephanie Eken, Chief Medical Officer, LifeStance Health
“Too many patients are still waiting for relief when there are effective, evidence-based treatment options that may help.”
Dr. Stephanie Eken, Chief Medical Officer, LifeStance Health
“We’re committed to expanding access to these specialty services so more patients have the opportunity to receive the most effective treatments tailored to their individual clinical needs.”
LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows PR Newswire
LifeStance Expands Specialty Services, Increasing Access to Esketamine (Spravato) and Transcranial Magnetic Stimulation (TMS) Across the U.S.
Get started
Create a free account to read the full story.